Total Payments
$74,588
2024 Payments
$8,339
Companies
20
Transactions
77
Medicare Patients
915
Medicare Billing
$128,744
Payment Breakdown by Category
Consulting$63,847 (85.6%)
Other$3,988 (5.3%)
Research$2,987 (4.0%)
Travel$1,994 (2.7%)
Food & Beverage$1,737 (2.3%)
Education$35.47 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $63,847 | 28 | 85.6% |
| Honoraria | $3,988 | 2 | 5.3% |
| Unspecified | $2,987 | 3 | 4.0% |
| Travel and Lodging | $1,994 | 9 | 2.7% |
| Food and Beverage | $1,737 | 33 | 2.3% |
| Education | $35.47 | 2 | 0.0% |
Payments by Type
General
$71,601
74 transactions
Research
$2,987
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $13,013 | 13 | $0 (2021) |
| Celgene Corporation | $12,193 | 11 | $0 (2020) |
| AbbVie Inc. | $5,740 | 9 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $5,562 | 5 | $0 (2024) |
| Genentech, Inc. | $4,986 | 2 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $4,407 | 5 | $0 (2017) |
| Seattle Genetics, Inc. | $3,716 | 9 | $0 (2017) |
| Bayer HealthCare Pharmaceuticals Inc. | $3,348 | 6 | $0 (2019) |
| Janssen Biotech, Inc. | $3,220 | 2 | $0 (2017) |
| Genmab U.S., Inc. | $2,777 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,339 | 7 | Regeneron Pharmaceuticals, Inc. ($5,562) |
| 2023 | $81.20 | 2 | AbbVie Inc. ($57.70) |
| 2021 | $4,062 | 3 | Gilead Sciences, Inc. ($2,850) |
| 2020 | $8,178 | 6 | Janssen Global Services, LLC ($2,525) |
| 2019 | $14,572 | 10 | Celgene Corporation ($6,866) |
| 2018 | $15,904 | 22 | Gilead Sciences, Inc. ($8,583) |
| 2017 | $23,451 | 27 | AstraZeneca Pharmaceuticals LP ($4,407) |
All Payment Transactions
77 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/15/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Consulting Fee | Cash or cash equivalent | $2,551.25 | General |
| Category: Oncology | ||||||
| 07/15/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $225.87 | General |
| Category: Oncology | ||||||
| 07/12/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,781.00 | General |
| 07/12/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,390.50 | General |
| 07/12/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $463.50 | General |
| 07/12/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $463.50 | General |
| 07/12/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $463.50 | General |
| 12/12/2023 | AbbVie Inc. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $57.70 | General |
| Category: ONCOLOGY | ||||||
| 03/31/2023 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Education | In-kind items and services | $23.50 | General |
| Category: Monoclonal Antibody | ||||||
| 08/11/2021 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | ||||||
| 04/05/2021 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $11.97 | General |
| Category: ONCOLOGY | ||||||
| 02/26/2021 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,850.00 | General |
| 12/10/2020 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $1,845.00 | General |
| 07/31/2020 | Celgene Corporation | Rituxan (Drug) | Consulting Fee | Cash or cash equivalent | $2,320.00 | General |
| Category: Hematology | ||||||
| 07/31/2020 | Janssen Global Services, LLC | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $1,010.00 | General |
| Category: Oncology | ||||||
| 07/17/2020 | Janssen Global Services, LLC | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $505.00 | General |
| Category: Oncology | ||||||
| 06/05/2020 | Janssen Global Services, LLC | IMBRUVICA (Drug) | Consulting Fee | Cash or cash equivalent | $1,010.00 | General |
| Category: Oncology | ||||||
| 05/15/2020 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Honoraria | Cash or cash equivalent | $1,488.00 | General |
| Category: Oncology | ||||||
| 12/05/2019 | F. Hoffmann-La Roche AG | VENCLEXTA (Biological) | Consulting Fee | Cash or cash equivalent | $1,320.00 | General |
| Category: BioOncology | ||||||
| 11/27/2019 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $6,750.00 | General |
| 11/23/2019 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $51.21 | General |
| 11/23/2019 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $28.98 | General |
| 11/23/2019 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $13.50 | General |
| 11/23/2019 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $13.33 | General |
| 11/23/2019 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $9.35 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-486-DLBCL-001 | Celgene Corporation | $1,463 | 1 |
| CC-122-DLBCL-001 - A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | Celgene Corporation | $1,082 | 1 |
| CC-486-DLBCL-001 - (AZA-JMML-001) PhII Azacitidine Open-label PK, Pharmacodynamics, Safety, Activity vs Historical Controls in Peds With ND Advanced MDS | Celgene Corporation | $442.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 210 | 356 | $146,477 | $29,231 |
| 2022 | 6 | 199 | 374 | $139,147 | $30,203 |
| 2021 | 8 | 262 | 387 | $146,225 | $32,618 |
| 2020 | 8 | 244 | 493 | $174,564 | $36,693 |
Total Patients
915
Total Services
1,610
Medicare Billing
$128,744
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 100 | 188 | $66,596 | $13,400 | 20.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 25 | 78 | $32,376 | $7,260 | 22.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 22 | 22 | $17,278 | $3,267 | 18.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 21 | $17,974 | $2,832 | 15.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 23 | 27 | $6,505 | $1,313 | 20.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 20 | 20 | $5,748 | $1,160 | 20.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 95 | 211 | $71,042 | $15,824 | 22.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 21 | 71 | $28,342 | $6,103 | 21.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 20 | 20 | $14,876 | $2,951 | 19.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 14 | $10,921 | $2,334 | 21.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 37 | 45 | $10,386 | $2,208 | 21.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 12 | 13 | $3,580 | $783.37 | 21.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 81 | 120 | $39,602 | $9,538 | 24.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 31 | 32 | $27,277 | $5,527 | 20.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 17 | 55 | $21,055 | $4,743 | 22.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 73 | 97 | $21,366 | $4,665 | 21.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 20 | 20 | $14,476 | $3,082 | 21.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 17 | 23 | $11,887 | $2,969 | 25.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 11 | 28 | $7,358 | $1,349 | 18.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 12 | 12 | $3,204 | $745.56 | 23.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 89 | 195 | $61,561 | $12,367 | 20.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 24 | 119 | $43,616 | $9,874 | 22.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 23 | 23 | $16,045 | $3,430 | 21.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 17 | 53 | $13,653 | $3,332 | 24.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 27 | 34 | $17,435 | $3,216 | 18.4% |
About Sonali Smith
Sonali Smith is a Hematology & Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/18/2007. The National Provider Identifier (NPI) number assigned to this provider is 1215153226.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Sonali Smith has received a total of $74,588 in payments from pharmaceutical and medical device companies, with $8,339 received in 2024. These payments were reported across 77 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($63,847).
As a Medicare-enrolled provider, Smith has provided services to 915 Medicare beneficiaries, totaling 1,610 services with total Medicare billing of $128,744. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Chicago, IL
- Active Since 04/18/2007
- Last Updated 10/24/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1215153226
Products in Payments
- Zydelig (Drug) $10,163
- IMBRUVICA (Drug) $5,745
- SGN35 (Biological) $3,716
- Aliqopa (Drug) $3,348
- Epkinly (Drug) $2,777
- Yescarta (Drug) $2,514
- Imbruvica (Drug) $2,500
- Rituxan (Drug) $2,320
- OPDIVO (Biological) $2,200
- CC-486 (Drug) $1,905
- XPOVIO (Drug) $1,488
- VENCLEXTA (Biological) $1,356
- Venclexta (Drug) $1,316
- clonoSEQ (Device) $1,200
- CC-122 (Drug) $1,082
- EPKINLY (Drug) $57.70
- Poteligeo (Drug) $23.50
- Revlimid (Drug) $19.60
- BELEODAQ (Drug) $11.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Chicago
Michael Bishop
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Young Kwang Chae, Md, Mph, Mba, MD, MPH, MBA
Hematology & Oncology — Payments: $682,642
Hematology & Oncology $682,642
Irfan Mirza, Md, MD
Hematology & Oncology — Payments: $644,273
Hematology & Oncology $644,273
Everett Vokes
Hematology & Oncology — Payments: $449,910
Hematology & Oncology $449,910
Peter Riedell
Hematology & Oncology — Payments: $374,919
Hematology & Oncology $374,919
Rita Nanda
Hematology & Oncology — Payments: $374,678
Hematology & Oncology $374,678